Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Clearmind Medicine Inc (CSE: CMND ) N/A UNCHANGED Last Price Updated: 3:54 PM EDT, Mar 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Clearmind Medicine Inc < Previous 1 2 3 4 Next > Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds February 22, 2023 From Clearmind Medicine Inc. Via GlobeNewswire SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US February 15, 2023 From SciSparc Ltd Via GlobeNewswire Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US February 15, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv February 14, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity February 08, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound January 31, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023 January 25, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum January 19, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment January 17, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial January 10, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial January 05, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com January 04, 2023 Via ACCESSWIRE Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND) January 03, 2023 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For AUD ($CMND) December 29, 2022 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Product Safety Clearmind Medicine Announces Shareholders Meeting Results December 29, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder December 28, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Inc. Scores Milestone Patent Issuance To Expedite And Protect Psychedelic-Based Treatment For AUD ($CMND) December 27, 2022 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute December 21, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Inc. Is Disrupting The Pharmaceuticals Landscape; First-To-Market Psychedelic-Based Treatment For AUD In Its Crosshairs ($CMND) December 21, 2022 Via AB Newswire Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders December 15, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100 December 13, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute December 09, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial November 23, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market November 17, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Announces Pricing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market November 14, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV October 11, 2022 From Clearmind Medicine Inc. Via GlobeNewswire Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics June 07, 2022 Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... Via FinancialNewsMedia Exposures COVID-19 Global Psychedelics Market Is Expected To Reach $8 Billion By 2029 May 24, 2022 Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster... Via FinancialNewsMedia InvestorNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) to Host Third Event in Psychedelics for Alcoholism Series February 01, 2022 Via Investor Brand Network BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event January 31, 2022 Via Investor Brand Network < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.